Actively Recruiting
Phase IIb Study of BP1001-A Alone and With Paclitaxel in Adults With Advanced or Recurrent Solid Tumors
Led by Bio-Path Holdings, Inc. · Updated on 2025-03-07
50
Participants Needed
4
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying BP1001-A, a liposomal Grb2 antisense oligonucleotide, in adults with advanced or recurrent solid tumors. This phase I, open-label trial aims to find the safety, maximum tolerated dose, and effects of BP1001-A alone and in combination with the chemotherapy drug paclitaxel. The study focuses on patients with various solid tumors, including ovarian, fallopian tube, endometrial, and peritoneal cancers who have limited treatment options. The trial has two parts a dose escalation phase where BP1001-A is given intravenously twice weekly for four weeks per cycle, for up to six cycles, to determine safe dosage levels and a dose expansion phase where the selected BP1001-A dose is combined with weekly paclitaxel infusions for similar cycles. Participants in the expansion phase must have specific tumor types suitable for paclitaxel treatment. Both phases monitor how well patients tolerate the treatments and assess responses. Participants will undergo biopsies before and after treatment cycles to evaluate tumor response. Safety is closely monitored through adverse event reporting and blood tests. The study measures outcomes including dose-limiting toxicities, treatment-emergent side effects, tumor response rates by imaging and biopsy, and pharmacokinetics of BP1001-A alone and with paclitaxel. The total observation period for key outcomes extends up to 360 days, with detailed follow-up to track progression and treatment effects.
CONDITIONS
Brief Title
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Research Team
B
Brian Forbes
M
Michael Hickey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here